A*STAR cancer therapy enters Phase I study

Singapore's Agency for Science, Technology, and Research and Duke- National University of Singapore Graduate Medical School (Duke-NUS) said a Phase I trial began last month of ECT-159, the first publicly-funded drug candidate discovered and developed in Singapore.

The study is evaluating safety and tolerability of ECT-159, which inhibits Wnt signaling, in patients with solid tumors. A*STAR said it has therapeutic potential in colorectal, ovarian and pancreatic cancers. ...